Intellectual disability (ID) is a clinically and genetically heterogeneous develop-
CASE PRESENTATIONS
Patient MR94 II-1 was a 7-yr-old boy born to nonconsanguineous Japanese parents. He was born through normal delivery without asphyxia at 38 wk of gestation. His weight and head circumferences were 2720 g (−0.7 SD) and 31.5 cm (−1.3 SD), respectively. He acquired head control after age 3 yr, sat independently after age 6, but could not form words. He had a febrile convulsion at the age of 2 yr. When he was 5 yr old, his developmental quotient (DQ) was 12. When he was 6 yr 3 mo old, he suffered spastic quadriplegia and horizontal nystagmus. He showed no aggressive, hyperactive, or self-harming behavior but did show autistic stereotype movement. Hypotonia in his trunk, extremities, and facial muscles was noted. His height, weight, and head circumference were 100 cm (−3.0 SD), 14.6 kg (−1.8 SD), and 47 cm (−2.6 SD), respectively. Brain magnetic resonance imaging (MRI) showed cerebral white matter and midbrain atrophy, and a thin corpus callosum ( Fig. 1AB ; Table 1 ). His 
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younger brother (MR94 II-2) also had X-linked intellectual disability (XLID). He was delivered by Caesarean section because of the breech presentation without asphyxia at 38 wk of gestation. His weight and head circumferences were 2878 g (−0.3 SD) and 30.5 cm (−2.0 SD), respectively. He rolled over after he was 1 yr old, but at the age of 1 yr and 2 mo, he had no head control, could not form words, and had a DQ < 10. He also showed spastic quadriplegia. His height, weight, and head circumference were 70 cm (−2.7 SD), 6.8 kg (−3.1SD), and 43 cm (−2.3 SD), respectively. No behavioral problems were noted, but autistic features were observed. Hypotonia in his trunk, extremities, and facial muscles was also noted. A brain MRI showed cerebral atrophy, myelination delay, and a thin corpus callosum (Fig. 1C ).
VARIANT INTERPRETATION
We identified a hemizygous missense variant, c.1282T>A (p.W428R; GRch37. Chr X. 110439743), in the p21-activated serine/threonine kinase 3 gene (PAK3: NM_002578.3; OMIM300142) in MR94 II-1 and MR94 II-2 ( Fig. 1D ,E; Table 2 ). The variant was inherited from their mother, who is asymptomatic. The altered amino acid residue (p.W428) is located within the highly conserved kinase domain. The tryptophan residue is conserved from human to zebrafish (Supplemental Fig. 1 ). Hence, we expected that the variant would abolish the kinase activity of PAK3. A c.1282T>A variant in PAK3 has not been deposited in any database, including dbSNP build 151, ESP6500, 1000 Genomes, the Exome Aggregation Consortium, the Human Genetic Variation Database, the Genome Aggregation Database (gnomAD), Novel PAK3 pathogenic variants in XLID
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ClinVar, or the Medical Genomics Japan Variant Database (as of the middle of December, 2018). We also searched the data from 3275 members of the Japanese general population acquired using high-depth whole-genome sequencing (Okada et al. 2018 ). However, not even a heterozygous carrier was found. Hence, the PAK3 variant identified in this study is considered to be "an extremely rare variant." In addition, three mutation prediction tools, SIFT, PolyPhen-2, and MutationTaster, predicted the mutation to be "Damaging," with a score of 0, "Probably damaging," with a score 1, and "Disease causing," with a score of 0.99, respectively. Finally, we classified and evaluated this variant using the guidelines for the classification of sequence variants from the American College of Medical Genetics and Genomics (Richards et al. 2015) . We concluded that the variant identified in this family is "Class 4 (likely pathogenic)" (Supplemental Table 1 ). No pathogenic variants in other genes are identified. Array comparative genomic hybridization (aCGH) analyses in both parents and patients also identified no pathogenic copy number variants (Supplemental Table 2 ).
SUMMARY
Families with a Chromosome X-linked inheritance pattern ID account for 5%-10% of all ID cases, suggesting an important role of the genes mutated on the X chromosome in males (Lubs et al. 2012 ). X-linked intellectual disability is divided into syndromic XLID (S-XLID) and nonsyndromic XLID (NS-XLID), the latter lacking dysmorphic features or other distinguishing symptoms (Ropers and Hamel 2005) . To date, at least 141 genes responsible for S-XLID and NS-XLID have been reported (Neri et al. 2018 ). Among them, PAK3 was identified as the causative gene in patients with NS-XLID (OMIM300558; MRX30) (Allen et al. 1998 ). Currently, 10 types of point mutations, one splicing mutation, one small deletion, and a 90-kb deletion containing exons 6-18 are described in the Human Gene Mutation Database, Professional (Version: 2018.3) as of the middle of December, 2018. These are all found in non-Japanese individuals. The clinical phenotypes of the patients with PAK3 mutations are variable, as summarized (Table 1 ; Supplemental Table 3 ). We noted several common features, including mild to severe ID (89.5%), language impairment (97.3%), and global developmental delay (78%), as also reported previously (Hertecant et al. 2017; Horvath et al. 2018) . Microcephaly (35.0%) and hypotonia (trunk and extremities, 34.3%; face, 30.8%) may represent characteristic features of the patients with PAK3 mutations. Spastic paraplegia/hemiplegia (10%) and nystagmus (10%) were also found in multiple cases. Less frequent and nonspecific features include epileptic seizures (23.1%), autistic features (15.8%), aggressive behavior/self-injury (26.3%), and short stature (15.8%). Imaging findings were available only in a small number of patients, but hypoplasia of corpus callosum (66.7%), atrophy of midbrain (30.0%), and white matter (25%) were reported.
Our cases showed all features in Table 1 except for aggressive behavior. They also showed more severe ID compared with previously reported patients, suggesting that they had the most severe form of the disease caused by PAK3 mutations. Spastic quadriplegia 
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and nystagmus appear to be rare phenotypes, but similar manifestations (i.e., lower limb spasticity and hemiplegia and oculomotor abnormalities) were also reported in other patients, suggesting that these features are possibly associated with PAK3 mutations. Hertecant et al. (2017) reported a monozygotic twin who presented with ID, behavioral problems, and unique macrocephaly caused by a p.Y427H mutation in PAK3, which is located one amino acid prior to the residue mutated in the present patients, who had acquired microcephaly, as seen in other patients. Reason for this opposite phenotypic expression remains unknown.
In conclusion, we report the first Japanese XLID family with a novel hemizygous PAK3 mutation. The literature review illustrated the phenotypic spectrum of PAK3-associated XLID and suggested that our cases represent a severe form of the disease.
METHODS
The biobank at the National Center of Neurology and Psychiatry is part of the National BioBank Network in Japan, which is a unique biorepository exclusively dedicated to collecting samples from patients with neuropsychiatric, muscular, and developmental diseases. The biobank contains DNA samples and clinical information from 583 families with neurodevelopmental diseases that were preserved and diagnosed from 2004 to 2016.
We performed exome sequencing to identify the causative gene in the family. Genomic DNAs were extracted from the patients and the parent's bloods by standard protocol. DNAs were processed by SureSelect XT Human All Exon V6 (Agilent Technologies) and BGISEQ DNA library preparation kit (BGI). Captured DNAs were sequenced using MGISEQ2000 (BGI) with 100-bp pair-end reads. Reads were mapped to the human genome reference (GRCh37/hg19) by BWA 0.7.5a-r405. Duplicated reads were removed by Picard 1.99. Variants were identified by Genome Analysis Toolkit v3.5 based on GATK Best Practice Workflow and annotated by ANNOVAR (2018 April 16). In all subjects, at least 98.1% of all coding regions were covered in 10 reads depth (Supplemental Table 4 ). The variant in PAK3 was confirmed by Sanger sequencing.
For the aCGH analysis, we utilized SurePrint G3 Human CGH microarray 8 × 60K (Agilent). The experimental procedures were performed according to the manufacturer's protocol (Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis, Version 7.2, Agilent Technologies).
The following Web resources were used:
• dbSNP build 151: https://www.ncbi.nlm.nih.gov/projects/SNP/ 
